Short answer
Sana Biotechnology, Inc. (SANA) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$64M
- +32.2% YoY · −34.8% QoQ
- EPS (diluted)
- −$0.22
- +43.6% YoY · −29.4% QoQ
Source: XBRL data from the Sana Biotechnology, Inc. (SANA) Q2 2026 10-Q on SEC EDGAR. USD.
Sana Biotechnology, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes from latest 10-K indicated; principal risks remain carried forward
- Regulatory risk: FDA class-wide boxed warnings for CAR T therapies following T-cell malignancies
- Technology risk: novel PSC-derived and fusogen platforms lack FDA-approved therapeutic precedent
- Operational risk: portfolio prioritization suspended two allogeneic CAR T programs
- Financial risk: substantial doubt regarding ability to continue as a going concern and need for additional funding
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sana Biotechnology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.